{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:40:17Z","timestamp":1789191617170,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.cct.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T03:31:39Z","timestamp":1477020699000},"page":"56-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"special_numbering":"C","title":["ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7057-1760","authenticated-orcid":false,"given":"Christopher","family":"Coyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fay H.","family":"Cafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy","family":"Berkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C S","family":"Pramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Kynaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2016.10.004_bb0005","unstructured":"Cancer Research UK. CancerStats - Cancer Statistics for the UK. In."},{"key":"10.1016\/j.cct.2016.10.004_bb0010","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/annonc\/mds113","article-title":"Aspirin and cancer risk: a quantitative review to 2011","volume":"23","author":"Bosetti","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10549-015-3300-z","article-title":"Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies","volume":"150","author":"Zhong","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.cct.2016.10.004_bb0020","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2009.22.7918","article-title":"Aspirin intake and survival after breast cancer","volume":"28","author":"Holmes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0025","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/bjc.2014.264","article-title":"Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study","volume":"111","author":"Fraser","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cct.2016.10.004_bb0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.2009.1112","article-title":"Aspirin use and survival after diagnosis of colorectal cancer","volume":"302","author":"Chan","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2016.10.004_bb0035","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/bjc.2012.101","article-title":"Use of aspirin postdiagnosis improves survival for colon cancer patients","volume":"106","author":"Bastiaannet","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cct.2016.10.004_bb0040","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.ejca.2012.10.024","article-title":"Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality","volume":"49","author":"McCowan","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cct.2016.10.004_bb0045","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/bjc.2012.427","article-title":"Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study","volume":"107","author":"Walker","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cct.2016.10.004_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1200\/jco.2015.33.15_suppl.3504","article-title":"Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: a population-based study","volume":"33","author":"Bains","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jnci\/dju345","article-title":"Aspirin and COX-2 inhibitor use in patients with stage III colon cancer","volume":"107","author":"Ng","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cct.2016.10.004_bb0060","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1245\/s10434-009-0382-z","article-title":"A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia","volume":"16","author":"Liu","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0065","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/bjc.2016.65","article-title":"The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients","volume":"114","author":"van Staalduinen","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cct.2016.10.004_bb0070","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.ijrobp.2012.02.050","article-title":"Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy","volume":"84","author":"Zaorsky","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cct.2016.10.004_bb0075","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2011.41.0308","article-title":"Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy","volume":"30","author":"Choe","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0080","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1200\/JCO.2013.54.8875","article-title":"Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer","volume":"32","author":"Jacobs","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0085","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.10.004_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.10.004_bb0095","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.10.004_bb0100","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.10.004_bb0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial","volume":"159","author":"Cook","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cct.2016.10.004_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152402","article-title":"Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies","volume":"11","author":"Elwood","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2016.10.004_bb0115","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","volume":"378","author":"Burn","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.10.004_bb0120","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.cct.2016.10.004_bb0125","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7326\/M15-2112","article-title":"Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force","volume":"164","author":"Whitlock","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cct.2016.10.004_bb0130","article-title":"Estimates of benefits and harms of prophylactic use of aspirin in the general population","author":"Cuzick","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0135","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1046\/j.1532-5415.2001.49281.x","article-title":"The vulnerable elders survey (VES-13): a tool for identifying vulnerable elders in the community","volume":"49","author":"Saliba","year":"2001","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.cct.2016.10.004_bb0140","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0145","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0140-6736(09)60740-6","article-title":"Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial","volume":"373","author":"Ellis","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.10.004_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jnci\/djm287","article-title":"Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02 98 randomized trial","volume":"100","author":"Francis","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cct.2016.10.004_bb0155","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa0910320","article-title":"Adjuvant docetaxel for high-risk, node-negative breast cancer","volume":"363","author":"Martin","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.10.004_bb0160","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2010.33.0738","article-title":"Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial","volume":"29","author":"Badwe","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0165","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andre","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0170","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study","volume":"370","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.10.004_bb0175","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2006.10.4760","article-title":"Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer","volume":"25","author":"Kelsen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0180","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.10.004_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.10.004_bb0195","series-title":"The Royal College of Surgeons of England","article-title":"National oesophago-gastric cancer audit","author":"Groene","year":"2012"},{"key":"10.1016\/j.cct.2016.10.004_bb0200","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(05)67101-2","article-title":"Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)","volume":"366","author":"Bolla","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2016.10.004_bb0205","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cct.2016.10.004_bb0210","first-page":"13435","article-title":"The effect of prediagnostic aspirin use on the prognosis of stage III colorectal cancer","volume":"8","author":"Kim","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.cct.2016.10.004_bb0215","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/sim.4780090115","article-title":"The use of a run-in to enhance compliance","volume":"9","author":"Lang","year":"1990","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2016.10.004_bb0220","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas","volume":"348","author":"Baron","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.10.004_bb0225","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/sim.4780101010","article-title":"Estimating the effect of the run-in on the power of the physicians' health study","volume":"10","author":"Lang","year":"1991","journal-title":"Stat. Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416303652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416303652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T17:56:53Z","timestamp":1568483813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714416303652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":45,"alternative-id":["S1551714416303652"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2016.10.004","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}